anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
[Problem] To provide a material which is for improving the gloss of hair and body hair of an animal and is made of a fibrous structure. [Solution] This material for improving hair gloss employs a fibrous structure that comprises a synthetic fiber to which an amino acid derivative is ionically bonded. The fibrous structure, to which an amino acid derivative is ionically bonded, gradually releases the amino acid derivative from the fibrous structure. By bringing the fibrous structure into contact with hair, the amino acid derivative transfers to the hair, and the absorption of internal scattered light by the hair is enhanced, thereby improving hair gloss. Thus, when an animal wears such a fibrous structure, that is, a fibrous structure processed into a garment shape, hair gloss can be naturally improved. The present invention can be mainly applied to mammals including humans.
A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
Background: Migraine is a common headache that can significantly impair the lives of otherwise normally functioning people. Several drugs are used individually for migraine prophylaxis, all of which have varying degrees of adverse effects, that may significantly limit their use. There is a need for effective, well tolerated and affordable drug for chronic migraine prophylaxis either alone or in combination in low socioeconomic countries.

To study and compare the efficacy and safety of Topiramte ,Amitrptyline monotherapy and combination therapy as prophylactic treatment in migraine patients .This single center, open label clinical trial will be conducted in Dhaka medical college and hospital . Patients who matches the inclusion and exclusion criteria will be enrolled in the study after taking written informed consent from all who agrees to participate. Migraine will be diagnosed according to the criteria of the Headache Classification Committee of the International Headache Society (3rd edition). After enrollment Simple random sampling will be done by parallel design as 1:1:1. Total 150 patients with migraine will be subdivided into three group: group A (n=50) will be treated with Topiramate and group B (n=50) with Amitriptyline and group C (n=50) with Topiramate plus Amitriptyline combination . Topiramate will be given to group A as 25 mg daily for first week ,then 25 mg twice daily till the end of the study. Group B will receive Amitriptyline 10mg daily for first week then 25mg daily till the end of the study. Group C will receive Topiramate 25 mg daily plus Amitrityline 10mg daily for first week then Topiramate 25 mg twice daily plus Amitrityline 25mg daily till the end of the study. Day 1 will be date of randomization and taking drug. Frequency, severity ,duration of headache and headache impact severity will be recorded at the biginning of study and end of 8 weeks and 12 weeks of treatment period. The patients will maintain a headache diary during the whole period. Information on demographic characteristics and migraine symptoms ,signs will be collected by a structured questionnaire .The evaluation of the treatment at the end of 8 weeks and 12 weeks of treatment period will be done by direct or telephonic interview . The outcome measures will be reduction of headache frequency and severity (using visual analogue scale of pain), duration of headache and improvement of headache impact (using HIT-6 scoring). Throughout the study, patients will be monitored for any symptoms or signs of adverse effects.
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to novel thiazole derivatives of the formula (I)   wherein R 1  means (a)  , (b)   or (c)  ; R 2  means (II)  ; R 3  means hydrogen atom, lower alkyl; R 4  means phenyl; R 5 -R 8  mean hydrogen atom; R 9  means hydrogen atom; R 10  means hydrogen atom, phenyl; A means oxygen atom, -CH=CH- and so on; arylene represents phenylene or substituted phenylene where substituents are taken among alkoxy-group and so on; symbols from a to f = 0 or mean whole positive figures, and so on; and to their pharmaceutically acceptable salts and esters. Invention relates also to method for preparing compound of the formula (I) by interaction of compound of the formula (XVIII)   with amine of the formula (XIX)  . Invention relates also to pharmaceutical composition eliciting effect of antagonist of vitronectin receptor and containing compound of the formula (I) as an active substance and therapeutically inert carrier. Invention provides preparing novel compounds eliciting effect of antagonist of vitronectin receptor. EFFECT: improved preparing method, valuable medicinal properties of compounds. 15 cl, 1 tbl, 21 ex
Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in consisting of three to eight 60-minute sessions that will occur consecutively. Each group will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
The subject matter described herein includes methods, systems, and computer readable media for automated behavioral assessment. According to one aspect, a method for automated behavioral assessment is provided. The method occurs at a computing platform including a processor and memory. The method includes providing at least one stimulus for eliciting a response from a user. The method also includes obtaining, using a camera or sensor communicatively coupled to the computing platform, the at least one response. The method also includes determining, using the at least one response, a behavioral assessment associated with the user.
In addition to standard of care participants will be asked to apply Tai Chi. There are 8 movements. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: Ward-off, Rollback, Push, Press, Grab, Split, Elbow strike, and shoulder strike.
The Type 2 Diabetes Exemplar Programme has been designed as a collaborative effort through partners from the Discover-NOW Health Data Research Hub in North West London (NWL). The remote care service is being used in primary care to demonstrate how data and technology can improve health outcomes for people living with T2DM. The service has been designed via a cross-industry collaboration between North West London Clinical Commissioning Groups (NWL CCGs), AstraZeneca, Imperial College Health Partners and Huma. The service will be offered for patients at high risk of developing complications from T2DM (such as heart attack and stroke) and will combine video group consultations, remote monitoring via a smartphone app, and educational content such as lifestyle and diet advice.

This service seeks to strengthen population health management by providing better-tailored services and proactive interventions, particularly among population groups more at risk of the adverse impacts of COVID-19. Mortality risk from COVID-19 is approximately 25% higher in patients with T2DM and shielding has resulted in reduced primary care appointments for patients with T2DM. This has created an immediate need for primary care to adapt to provide care remotely to people with T2DM. Digital-first remote pathways could make care more accessible while finding time and cost efficiencies. By combining video group consultations and remote monitoring, we can inform the patient-clinician conversation making remote care in group settings safer, efficient and more personalised.
OBJECTIVE: The purpose of this study was to determine the reliability and validity of the pressure algometer in predicting gynecological surgery pain. We looked into the predictive value of preoperative pain sensitivity to gynecological pain and the relationship between preoperative pressure pain threshold (PPT), pressure pain tolerance (PTO), and postoperative pain outcomes.
METHODS: Reliability test: We recruited 60 volunteers at Nantong University. For three consecutive days, two examiners measured the pain sensitivity of each participant using a pressure algometer. Its test-retest and intra-rater reliability were assessed using the intraclass correlation coefficient (ICC). Validity test: We selected patients who underwent gynecological surgery in a hospital for the validity test. Before surgery, we assessed the patient's pain sensitivity to various stimuli. To determine the relationship between preoperative pain sensitivity and postoperative pain, we collected postoperative Numerical Rating Scale (NRS) and sufentanil consumption data.
RESULTS: The algometer revealed a high test-retest and intra-rater reliability. According to the calculation of Youden's index, there was a 73.1% chance of patients with moderate to severe postoperative pain having a PTO <6.22 N, and patients with PTO <6.22 N had an 87.5% probability of moderate to severe postoperative pain.
CONCLUSIONS: The pressure algometer has a high degree of accuracy in measuring the PPT and PTO of normal healthy individuals, making it a reliable tool for quantifying pain sensitivity. PTO can be used to predict the occurrence of moderate to severe postoperative pain.
The invention relates to a composition used for treating gastric diseases, and a preparation method thereof. The invention relates to a medicine. The composition comprises largehead atractylodes rhizome, corydalis tuber, panax notoginseng, common monkshood daughter root, hedgehog hydnu, white peony root, mix-fried licorice root, and green walnut. The materials are subjected to low-temperature bake-drying and mixed crushing; the obtained mixture is placed into a vessel; distillate spirit is added; and the mixture is sealed and placed for 60 days; the obtained product is bottled in bottles, such that finished products are obtained. According to the invention, largehead atractylodes rhizome, corydalis tuber, panax notoginseng, common monkshood daughter root, hedgehog hydnu, white peony root, mix-fried licorice root, and green walnut are subjected to low-temperature bake-drying, such that medicine effect damage is prevented in the subsequent crushing process. The medicine materials are crushed and mixed, such that discomfort medication reaction caused by non-uniform mixing is prevented. With the soaking decomposition effect of the distillate spirit, the medicine materials are fused and blended, and toxicities are offset.
PURPOSE: Rhabdomyolysis is a clinical syndrome with the potential to cause cardiac arrhythmias, renal failure, and even death. Currently, there are no studies regarding risk factors for developing post-operative rhabdomyolysis (POR) after spinal fusion surgeries. Our objective was to study risk factors associated with, and to develop a decision-making framework for post-operative rhabdomyolysis after spinal fusion surgery.
METHODS: We performed a retrospective cohort study of all spinal fusions of three or more levels over 2.25 years by a single surgeon at two centers. POR was defined as a creatine phosphokinase (CPK) greater than 2000 IU/L.
RESULTS: 76 surgical procedures on 72 patients were identified. Rate of POR in our cohort was 22% (17/76). Male sex was associated with POR (p < 0.05). Previously validated risk factors: younger age, lower ASA score, elevated BMI, higher pre-operative creatinine, increased intraoperative blood loss, specific surgical positions, and length of surgery, were not associated with POR. In a logistic regression model, male gender increases the odds of POR in all patients 5.82-fold (p = 0.047). In patients without a second surgery within seven days, a logistic regression model suggests each additional level fused via transpsoas approach, and male gender, increases the risk of POR 1.81-times (p = 0.015), and 6.26-times (p = 0.047), respectively. In patients with posterior fusions, a logistic regression model suggests increasing the number of lateral levels fused via transpsoas approach in the same surgery, and male gender, increases the risk of POR 1.68-times and 6.34-times, respectively. In these same subgroups, increased thickness of the psoas major in lateral transpsoas fusions increased risk of POR (p = 0.023, p = 0.046, respectively).
CONCLUSIONS: In spinal fusions, increasing the number of lateral levels fused via transpsoas approach, and male gender, predispose patients to increased risk of POR in those without a second surgery within seven days, and in those with a simultaneous posterior fusion.
Patient with an indication of transurethral resection of the bladder. Following the Urology consultation, the patient will be called for a trans-urethral bladder resection within 1 month. The patient will be admitted to the Urology Department of the Tours University Hospital the previous day.
Subjects will receive HF care as usually provided by their physician as advised or as needed. Study commitments for the control group include the initial interview, the expected time allotment for this initial visit is 1 hour. Telephone follow-up will occur at 3 months and 9 months to collect exacerbation data and maintain contact with participant. At 6 months and 12 months telephone follow-up will be conducted by the research assistant and the questionnaires will be completed.
The invention provides compounds of the general formula   CH3 - @@ - O-CO - X, wherein X is -Cl, Br or -OCH2CH3, and the preparation thereof. One such compound, 1-bromoethyl ethyl carbonate, is useful as an esterification agent, e.g. for penicillins, and the other such compounds are intermediates in its preparation. The manufacture of formulations containing 1 min -ethoxy-carbonyloxy ethyl esters of penicillins is included in the invention. There are also provided novel compounds of the formula <CHEM> in which Ph is phenyl and R is CH3- or C2H5-. l
BACKGROUND: Extrachromosomal circular DNA (eccDNA), a kind of circular DNA that originates from chromosomes, carries complete gene information, particularly the oncogenic genes. This study aimed to examine the contributions of FAM84B induced by eccDNA to prostate cancer (PCa) development and the biomolecules involved.
METHODS: The presence of eccDNA in PCa cells and the FAM84B transcripts that eccDNA carries were verified by outward and inward PCR. The effect of inhibition of eccDNA synthesis on FAM84B expression in PCa cells was analyzed by knocking down Lig3. The impact of FAM84B on the growth and metastases of PCa cells was verified by Cell Counting Kit-8 (CCK8), EdU, transwell assays, and a xenograft mouse model. Chromatin immunoprecipitation quantitative PCR (ChIP-qPCR) and dual-luciferase reporter assays were carried out to examine the effect of FAM84B/MYC on WWP1 transcription, and a co-immunoprecipitation (Co-IP) assay was conducted to verify the modification of CDKN1B by WWP1. The function of this molecular axis in PCa was explored by rescue assays.
RESULTS: The inhibited eccDNA synthesis significantly downregulated FAM84B in PCa cells, thereby attenuating the growth and metastasis of PCa. FAM84B promoted the transcription of WWP1 by MYC by activating the expression of MYC coterminous with the 8q24.21 gene desert in a beta catenin-dependent approach. WWP1 transcription promoted by MYC facilitated the ubiquitination and degradation of CDKN1B protein and inversely attenuated the repressive effect of CDKN1B on MYC expression. Exogenous overexpression of CDKN1B blocked FAM84B-activated MYC/WWP1 expression, thereby inhibiting PCa progression.
CONCLUSIONS: FAM84B promoted by eccDNA mediates degradation of CDKN1B via MYC/WWP1, thereby accelerating PCa progression.
As with other dopamine D2 receptor antagonists, metoclopramide elevates prolactin levels.

Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating drugs, including metoclopramide. 

Hyperprolactinemia may potentially stimulate prolactin-dependent breast cancer. However, some clinical studies and epidemiology studies have not shown an association between administration of dopamine D 2 receptor antagonists and tumorigenesis in humans [see Nonclinical Toxicology ( 13.1)].
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface. The use of this product by more than one person may spread infection.

Patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated products (see PRECAUTIONS: General).

If the condition persists or gets worse, or if a rash or allergic reaction develops, the patient should be advised to stop use and consult a physician. Do not use this product if you are allergic to any of the listed ingredients.

Keep tightly closed when not in use. Keep out of reach of children.
BACKGROUND: Bisphosphonates (BPs) are the first-line treatment to stop bone resorption in diseases, including osteoporosis, Paget's disease, multiple myeloma and bone metastases of cancer. However, BPs-related osteonecrosis of the jaw (BRONJ), characterized by local inflammation and jawbone necrosis, is a severe intractable complication. The cumulative inflammatory burden often accompanies impaired lymphatic drainage, but its specific impact on BRONJ and the underlying mechanisms remain unclear.
METHODS: The mouse BRONJ model was established to assess the integrity and drainage function of lymphatic vessels by tissue clearing techniques, injected indocyanine green lymphatic clearance assay, flow cytometry analysis and histopathological staining. RNA sequencing, metabolome analysis, transmission electron microscopy and Western blotting were utilized to analyze the impacts of Zoledronate acid (ZA) on endoplasmic reticulum stress (ERS) and function of lymphatic endothelial cells (LECs). By constructing Lyve1creERT; SIRT6f/f and Lyve1creERT; ATG5f/f mice, we evaluated the role of ERS-induced LECs apoptosis in the progression of BRONJ. Additionally, we developed a nanoparticle-loaded ZA and rapamycin (ZDPR) to enhance autophagy and evaluated its potential in mitigating BRONJ.
RESULTS: The mouse BRONJ model displayed impaired lymphatic drainage, accompanied by significant local inflammation and bone necrosis. The prolonged stimulation of ZA resulted in the extension of ERS and the inhibition of autophagy in LECs, ultimately leading to apoptosis. Mechanistically, ZA activated XBP1s through the NAD+/SIRT6 pathway, initiating ERS-induced apoptosis in LECs. The conditional knockout mouse models demonstrated that the deletion of SIRT6 or ATG5 significantly worsened lymphatic drainage and inflammatory infiltration in BRONJ. Additionally, the innovative nanoparticle ZDPR alleviated ERS-apoptosis in LECs and enhanced lymphatic function, facilitating inflammation resolution.
CONCLUSION: Our study has elucidated the role of the NAD+/SIRT6/XBP1s pathway in ERS-induced apoptosis in ZA-treated LECs, and further confirmed the therapeutic potential of ZDPR in restoring endothelial function and improving lymphatic drainage, thereby effectively mitigating BRONJ.
KEY POINTS: Bisphosphonate-induced lymphatic drainage impairment exacerbates bone necrosis. Zoledronate acid triggers endoplasmic reticulum stress and apoptosis in lymphatic endothelial cells via the NAD+/SIRT6/XBP1s pathway. Novel nanoparticle-loaded Zoledronate acid and rapamycin enhances autophagy, restores lymphatic function, and mitigates bisphosphonates-related osteonecrosis of the jaw progression.
The invention provides for a pocketed anchor for post-tensioned concrete reinforcement. The anchor includes a body having a flange portion with a front and rear surface, a button portion extending from the rear surface, and a nose portion extending from the front surface. The anchor also includes a tapered bore that extends through the nose, flange, and button portions. The bore can receive a wedge that cams against the bore to clamp down on a tendon. The front surface of the flange has at least two planar surfaces that are parallel to the bearing surface on the rear surface of the anchor. One of the planar surfaces is recessed relative to the other such that the recessed surface is closer to the load bearing surface on the rear surface of the anchor. The two planar surfaces define a pocket on the anchor, where mounting holes may be located.
The protein pRb2/p130 represses expression of the ER-.alpha. gene. Blocking pRb2/p130 expression or altering ER-.alpha. gene methylation to alter pRb2/p130 complex binding allows transcriptional activity of the ER-.alpha.  gene to be restored. Detecting and regulating the methylation state of the ER-.alpha. gene, optionally together with detecting and regulating pRb2/p130 multimolecular complexes bound to the ER-.alpha. gene promoter, allows estrogen-insensitive breast cancer cells to be identified, so that an accurate prognosis can be obtained and an appropriate course of treatment administered.  Also, inhibiting pRb2/p130, or altering the methylation pattern of the ER-.alpha. gene by targeting DNMT 1 I n the pRb2/p 130-E2F4/5-HDAC 1-DNMT1-SUV39H1 complex, allows estrogen-insensitive breast cancer cells to be converted to estrogen-sensitive breast cancer cells. Estrogen-sensitive breast cancer cells which are generally more susceptible to current anti-cancer treatments.
Participants will receive either BAY3283142 or placebo twice a day. The treatment scheme consists of 3 dose steps. Treatment will start with the low dose for 7 days , followed for 14 days at the middle dose and 14 days on the very high dose.
The invention relates to a cherry tea medicinal wine. The cherry tea medicinal wine comprises the following raw materials by weight: 20-25% of millet, 2-4% of tea, 15-35% of cherry, 15-30% of papaya, 2-3% of blueberry leaf, 2-3% of cassia seed, 1-2% of Radix Astragali, and 2-8% of cinnamon. The invention also discloses a making method of the cherry tea medicinal wine. The cherry tea medicinal wine provided by the invention has the rich nutrients, health functions and natural fragrance of tea, at the same time has the cereal aroma of millet, has richer nutrition, no bitter taste, mellow flavor, and layered taste and smell. After soaking, crushing and steaming, tea polyphenol and caffeine in the tea can be more fully dissolved out, thus being beneficial to human health. As the nutrients in fruit and tea are all dissolved out, relative to direct consumption of fruit flesh, the cherry tea medicinal wine is more easily absorbed by the human body.